NASDAQ:YMAB

Y-mAbs Therapeutics (YMAB) Price Target & Analyst Ratings

$8.16

-0.29 (-3.43%)

(As of 06/7/2023 ET)

Compare

Today's Range: $8.09
▼
$8.59
50-Day Range: $3.29
▼
$10.34
52-Week Range: $2.70
▼
$20.48

Volume: 236,397 shs
Average Volume: 567,169 shs
Market Capitalization: $356.43 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.67

Y-mAbs Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 12 Analyst Ratings

Consensus Analyst Price Target

$13.67
67.48% Upside

High Prediction	$27.00
Average Prediction	$13.67
Low Prediction	$4.00

Type	Current 6/8/22 to 6/8/23	1 Month Ago 5/9/22 to 5/9/23	3 Months Ago 3/10/22 to 3/10/23	1 Year Ago 6/8/21 to 6/8/22
Consensus Rating	Hold	Hold	Hold	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)	3 Buy rating(s)
Hold	5 Hold rating(s)	6 Hold rating(s)	5 Hold rating(s)	2 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$13.67	$12.11	$14.00	$31.60
Predicted Upside	67.48% Upside	109.81% Upside	133.08% Upside	158.21% Upside

Get Y-mAbs Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.

YMAB Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

YMAB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Y-mAbs Therapeutics Stock vs. The Competition

Type	Y-mAbs Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.25	2.66	2.49
Consensus Rating	Hold	Buy	Hold
Predicted Upside	67.48% Upside	1,238.86% Upside	228.69% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Historical Target Prices and Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
5/15/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$6.00 ➝ $12.00	+33.48%
5/10/2023	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Nierengarten Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$5.00 ➝ $13.00	+40.85%
4/4/2023	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$19.00 ➝ $11.00	+92.98%
4/3/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
3/31/2023	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$20.00 ➝ $18.00	+267.35%
1/30/2023	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$12.00 ➝ $13.00	+194.78%
1/27/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Equal Weight ➝ Underweight	$4.00	-12.09%
1/5/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
10/31/2022	Kempen & Co Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
10/31/2022	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underweight	$16.00 ➝ $7.00	-21.61%

(Data available from 6/8/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

YMAB Price Target - Frequently Asked Questions

What is Y-mAbs Therapeutics's consensus rating and price target?: According to the issued ratings of 12 analysts in the last year, the consensus rating for Y-mAbs Therapeutics stock is Hold based on the current 2 sell ratings, 5 hold ratings and 5 buy ratings for YMAB. The average twelve-month price prediction for Y-mAbs Therapeutics is $13.67 with a high price target of $27.00 and a low price target of $4.00. Learn more on YMAB's analyst rating history.
Do Wall Street analysts like Y-mAbs Therapeutics more than its competitors?: Analysts like Y-mAbs Therapeutics less than other Medical companies. The consensus rating for Y-mAbs Therapeutics is Hold while the average consensus rating for medical companies is Buy. Learn more on how YMAB compares to other companies.
Is Y-mAbs Therapeutics being upgraded or downgraded by Wall Street analysts?: Over the previous 90 days, Y-mAbs Therapeutics's stock had 1 upgrade and 1 downgrade by analysts.

Does Y-mAbs Therapeutics's stock price have much upside?: According to analysts, Y-mAbs Therapeutics's stock has a predicted upside of 124.87% based on their 12-month price targets.
What analysts cover Y-mAbs Therapeutics?: Y-mAbs Therapeutics has been rated by Bank of America, Canaccord Genuity Group, Guggenheim, HC Wainwright, and Wedbush in the past 90 days.

Stock Ratings Reports and Tools

This page (NASDAQ:YMAB) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial